Vitamin D for the management of multiple sclerosis.

What It Covers

The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of multiple sclerosis, published as a meta-analysis.

This review is an update of a previously published review, "Vitamin D for the management of multiple sclerosis" (published in the Cochrane Library; 2010, Issue 12).

Multiple sclerosis (MS) is characterised by inflammation, demyelination, axonal or neuronal loss, and astrocytic gliosis in the central nervous system (CNS), which can result in varying levels of disability.

How the Review Was Done

The researchers searched the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Specialized Register up to 2 October 2017 through contact with the Information Specialist with search terms relevant to this review.

The researchers included references identified from comprehensive electronic database searches and from handsearches of relevant journals and abstract books from conferences.

What Was Measured

Multiple sclerosis (MS) is characterised by inflammation, demyelination, axonal or neuronal loss, and astrocytic gliosis in the central nervous system (CNS), which can result in varying levels of disability.

Two review authors independently extracted data and assessed the methodological quality of studies, while another review author sorted any disagreements.

Topics PubMed links to this paper include Cholecalciferol, Ergocalciferols, Fatigue, Multiple Sclerosis, Quality of Life, Randomized Controlled Trials as Topic and Vitamins.

What This Means in Plain Language

This is a meta-analysis of Vitamin D, K2, Magnesium and Zinc in people with multiple sclerosis.

Results are reported in around 17 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2018 (The Cochrane database of systematic reviews), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Multiple sclerosis research.